Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic
therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther. 2021 Nov;21(11):1273-1286.
Strauss A, Schmid M, Rink M, Moran M, Bernhardt S, Hubbe M, Bergmann
L, Schlack K, Boegemann M. Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. Future Oncol. 2021
Jun;17(18):2325-2338.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE,
Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer
A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-1300.(Investigator)
Araujo-Fernandez I, Delgado J,
Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. The European Medicines Agency review of the initial application of atezolizumab
and the role of PD-L1 expression as biomarker for checkpoint inhibitors. ESMO Open. 2020 Dec 16;6(1):100008. doi: 10.1016/j.esmoop.2020.100008.
Bergmann
L, Grünwald V, Maute L, Grimm MO, Weikert S, Schleicher J, Klotz T, Greiner J, Flörcken A,
Hartmann A, Gauler T. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for
Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncol Res Treat. 2020;43(7-8):333-339.
Boegemann M, Schlack K, Rink M,
Bernhardt S, Moran M, Hubbe M, Bergmann L, Schmid M, Strauss A. Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR
registry. Future Oncol. 2020 Oct 6. doi: 10.2217/fon-2020-0548. Epub ahead of print. PMID: 33021843.
Miller K, Bergmann
L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Keilholz U, Kuczyk MA. Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms [Interdisciplinary
recommendations for the treatment of advanced metastatic renal cell carcinoma]. Aktuelle Urol. 2020 Oct 7. German. doi: 10.1055/a-1252-1780.
Goebell PJ, Ivanyi P, Bedke J,
Bergmann L, Berthold D, Boegemann M, Busch J, Doehn C, Krege S, Retz M, Amsberg GV, Grimm MO, Gruenwald V. Consensus paper: current state of first- and second-line therapy in
advanced clear-cell renal cell carcinoma. Future Oncol. 2020 Sep 23. doi: 10.2217/fon-2020-0403. Online ahead of print.
Ahrens M, Hartmann A,
Bergmann L. What is new in the diagnosis and therapy of renal cell
carcinoma? Dtsch Med Wochenschr. 2020 Jun;145(11):734-739.
Rexer H, Bergmann
L, Steiner T. A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or
metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO.Aktuelle Urol. 2020
Jun;51(3):236-238.
Donskov F, Motzer RJ, Voog E,
Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri
TK.Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients
with advanced renal cell carcinoma. Eur J Cancer. 2020 Feb;126:1-10.
Ahrens M, Scheich S, Hartmann A, Bergmann L.
IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society.Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Oncol Res Treat.
2019;42(3):128-135.
Miller K, Bergmann L, Doehn C, Gschwend JE,
Kuczyk MA.Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma.
Aktuelle Urol. 2019 Sep 4. doi: 10.1055/a-0972-0914. [Epub ahead of print] German
Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T,
Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty.
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer. 2019 Jun;114:128-136.
Goebell PJ, Hermann E, Kube U, Doehn C, Marschner N, Dietel A,
Blumenstengel K, Grimm MO, Scheffler M, Rogler A, Bergmann L. Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal
Cell Carcinoma with Everolimus: The EVERPRO Study.Oncol Res Treat. 2019;42(1-2):57-66.
*Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B,
Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y,
Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators (Bergmann, investigator).
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med. 2018 Apr 5;378(14):1277-1290
*Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C,
Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study (Bergmann,
investigator) .Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3
trial. Lancet Oncol. 2018 Nov;19(11):1530-1542
Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F,
Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U. Population Modeling
Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients with Sunitinib-Treated Cancer. CPT Pharmacometrics Syst Pharmacol. 2017
Sep;6(9):604-613.
Rexer H, Steiner T, Bergmann L. Nivolumab
combined with ipilimumab versus sunitinib monotherapy - SUNNIFORECAST AN 41/16 of the AUO: A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or
metastatic) non-clear cell renal cell carcinoma. Urologe A. 2017 Jun;56(6):802-803.
Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A,
Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC
Investigators.Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.N Engl J Med. 2016 Dec 8;375(23):2246-2254. *
Glienke W, Maute L, Wicht J, Bergmann L. Wilms’
Tumor Gene 1 (WT1) as a Target in Curcumin Treatment of Pancreatic Cancer Cells.Eur J Cancer, 2009,
2009 Mar;45(5):874-80. Epub 2009 Feb 3
Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for
Research and Treatment of Cancer.Eur J Cancer.2008 Aug;44(12):1657-62.
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A,
Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.Mutations and treatment outcome in
cytogenetically normal acute myeloid leukemia.N Engl J Med. 2008 May
1;358(18):1909-18. *
Bergmann L, Hirschfeld S, Morris C, Palmeri S, Stone A and Biotherapy Development Association (BDA). Progression-free survival as an
end-point in clinical trials of biotherapeutic agents.Eur J Cancer, 2007,
suppl.5:23-28
Bergmann L.. Erlotinib in pancreatic cancer.Eu J Cancer 2007, suppl.5: 7-8